These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 36314338)

  • 41. A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapy.
    Hurvitz SA; Dalenc F; Campone M; O'Regan RM; Tjan-Heijnen VC; Gligorov J; Llombart A; Jhangiani H; Mirshahidi HR; Tan-Chiu E; Miao S; El-Hashimy M; Lincy J; Taran T; Soria JC; Sahmoud T; André F
    Breast Cancer Res Treat; 2013 Oct; 141(3):437-46. PubMed ID: 24101324
    [TBL] [Abstract][Full Text] [Related]  

  • 42. CDK4/6 inhibitors versus PI3K/AKT/mTOR inhibitors in women with hormone receptor-positive, HER2-negative metastatic breast cancer: An updated systematic review and network meta-analysis of 28 randomized controlled trials.
    Xu H; Wang Y; Han Y; Wu Y; Wang J; Xu B
    Front Oncol; 2022; 12():956464. PubMed ID: 36091147
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Trastuzumab in combination with AT-101 induces cytotoxicity and apoptosis in Her2 positive breast cancer cells.
    Bulut G; Atmaca H; Karaca B
    Future Oncol; 2020 Jan; 16(3):4485-4495. PubMed ID: 31829029
    [No Abstract]   [Full Text] [Related]  

  • 44. Combination treatment with a PI3K/Akt/mTOR pathway inhibitor overcomes resistance to anti-HER2 therapy in PIK3CA-mutant HER2-positive breast cancer cells.
    Fujimoto Y; Morita TY; Ohashi A; Haeno H; Hakozaki Y; Fujii M; Kashima Y; Kobayashi SS; Mukohara T
    Sci Rep; 2020 Dec; 10(1):21762. PubMed ID: 33303839
    [TBL] [Abstract][Full Text] [Related]  

  • 45. PIKHER2: A phase IB study evaluating buparlisib in combination with lapatinib in trastuzumab-resistant HER2-positive advanced breast cancer.
    Guerin M; Rezai K; Isambert N; Campone M; Autret A; Pakradouni J; Provansal M; Camerlo J; Sabatier R; Bertucci F; Charafe-Jauffret E; Hervieu A; Extra JM; Viens P; Lokiec F; Boher JM; Gonçalves A
    Eur J Cancer; 2017 Nov; 86():28-36. PubMed ID: 28950146
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
    Chan A; Delaloge S; Holmes FA; Moy B; Iwata H; Harvey VJ; Robert NJ; Silovski T; Gokmen E; von Minckwitz G; Ejlertsen B; Chia SKL; Mansi J; Barrios CH; Gnant M; Buyse M; Gore I; Smith J; Harker G; Masuda N; Petrakova K; Zotano AG; Iannotti N; Rodriguez G; Tassone P; Wong A; Bryce R; Ye Y; Yao B; Martin M;
    Lancet Oncol; 2016 Mar; 17(3):367-377. PubMed ID: 26874901
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Increased signalling of EGFR and IGF1R, and deregulation of PTEN/PI3K/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas.
    Gallardo A; Lerma E; Escuin D; Tibau A; Muñoz J; Ojeda B; Barnadas A; Adrover E; Sánchez-Tejada L; Giner D; Ortiz-Martínez F; Peiró G
    Br J Cancer; 2012 Apr; 106(8):1367-73. PubMed ID: 22454081
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Risk of adverse events with the addition of targeted agents to endocrine therapy in patients with hormone receptor-positive metastatic breast cancer: A systematic review and meta-analysis.
    Martel S; Bruzzone M; Ceppi M; Maurer C; Ponde NF; Ferreira AR; Viglietti G; Del Mastro L; Prady C; de Azambuja E; Lambertini M
    Cancer Treat Rev; 2018 Jan; 62():123-132. PubMed ID: 29108713
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Alterations of the genes involved in the PI3K and estrogen-receptor pathways influence outcome in human epidermal growth factor receptor 2-positive and hormone receptor-positive breast cancer patients treated with trastuzumab-containing neoadjuvant chemotherapy.
    Takada M; Higuchi T; Tozuka K; Takei H; Haruta M; Watanabe J; Kasai F; Inoue K; Kurosumi M; Miyazaki M; Sato-Otsubo A; Ogawa S; Kaneko Y
    BMC Cancer; 2013 May; 13():241. PubMed ID: 23679233
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer: The NEfERT-T Randomized Clinical Trial.
    Awada A; Colomer R; Inoue K; Bondarenko I; Badwe RA; Demetriou G; Lee SC; Mehta AO; Kim SB; Bachelot T; Goswami C; Deo S; Bose R; Wong A; Xu F; Yao B; Bryce R; Carey LA
    JAMA Oncol; 2016 Dec; 2(12):1557-1564. PubMed ID: 27078022
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Efficacy and safety of trastuzumab deruxtecan in treating human epidermal growth factor receptor 2-low/positive advanced breast cancer:A meta-analysis of randomized controlled trials.
    Ma R; Shi Y; Yan R; Yin S; Bu H; Huang J
    Crit Rev Oncol Hematol; 2024 Apr; 196():104305. PubMed ID: 38442809
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Trastuzumab combined with doublet or single-agent chemotherapy as first-line therapy for HER2-positive metastatic breast cancer.
    Yu YF; Wang Y; Fu TP; Chen K; Liu JQ; Yao HR
    Breast Cancer Res Treat; 2018 Apr; 168(2):337-348. PubMed ID: 29188398
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Lapatinib and lapatinib plus trastuzumab therapy versus trastuzumab therapy for HER2 positive breast cancer patients: an updated systematic review and meta-analysis.
    Yuan Y; Liu X; Cai Y; Li W
    Syst Rev; 2022 Dec; 11(1):264. PubMed ID: 36496473
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinical significance of p95HER2 overexpression, PTEN loss and PI3K expression in p185HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies.
    Tural D; Serdengecti S; Demirelli F; Öztürk T; İlvan S; Turna H; Özgüroglu M; Büyükünal E
    Br J Cancer; 2014 Apr; 110(8):1968-76. PubMed ID: 24595002
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Frequent mutational activation of the PI3K-AKT pathway in trastuzumab-resistant breast cancer.
    Chandarlapaty S; Sakr RA; Giri D; Patil S; Heguy A; Morrow M; Modi S; Norton L; Rosen N; Hudis C; King TA
    Clin Cancer Res; 2012 Dec; 18(24):6784-91. PubMed ID: 23092874
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study.
    Tan AR; Im SA; Mattar A; Colomer R; Stroyakovskii D; Nowecki Z; De Laurentiis M; Pierga JY; Jung KH; Schem C; Hogea A; Badovinac Crnjevic T; Heeson S; Shivhare M; Kirschbrown WP; Restuccia E; Jackisch C;
    Lancet Oncol; 2021 Jan; 22(1):85-97. PubMed ID: 33357420
    [TBL] [Abstract][Full Text] [Related]  

  • 57. PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancer.
    Roncolato F; Lindemann K; Willson ML; Martyn J; Mileshkin L
    Cochrane Database Syst Rev; 2019 Oct; 10(10):CD012160. PubMed ID: 31588998
    [TBL] [Abstract][Full Text] [Related]  

  • 58.
    Dockx Y; Vangestel C; De Bruycker S; Van den Wyngaert T; Huizing M; Staelens S; Stroobants S
    Cancer Biother Radiopharm; 2023 Feb; 38(1):51-61. PubMed ID: 36472460
    [No Abstract]   [Full Text] [Related]  

  • 59. A Phase II Open Label Study of Everolimus in Combination With Endocrine Therapy in Resistant Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer.
    Yardley DA; Liggett W; Mainwaring M; Castrellon A; Blakely L; Hemphill B; Anz B; Young RR; Shastry M; DeBusk LM; Hainsworth JD; Burris HA
    Clin Breast Cancer; 2020 Apr; 20(2):89-97. PubMed ID: 31932237
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Defining biomarkers to predict sensitivity to PI3K/Akt/mTOR pathway inhibitors in breast cancer.
    Gonzalez-Angulo AM; Blumenschein GR
    Cancer Treat Rev; 2013 Jun; 39(4):313-20. PubMed ID: 23218708
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.